BRNS vs. IKT, TIL, ALEC, BDTX, GALT, NLTX, LXEO, LYEL, FTLF, and ALTS
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Inhibikase Therapeutics (IKT), Instil Bio (TIL), Alector (ALEC), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Neoleukin Therapeutics (NLTX), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), FitLife Brands (FTLF), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry.
Barinthus Biotherapeutics vs. Its Competitors
Barinthus Biotherapeutics (NASDAQ:BRNS) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Barinthus Biotherapeutics' return on equity of -46.43% beat Inhibikase Therapeutics' return on equity.
Barinthus Biotherapeutics currently has a consensus price target of $6.25, indicating a potential upside of 573.93%. Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 236.79%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than Inhibikase Therapeutics.
In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Inhibikase Therapeutics and 1 mentions for Barinthus Biotherapeutics. Inhibikase Therapeutics' average media sentiment score of 0.30 beat Barinthus Biotherapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.
25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Barinthus Biotherapeutics has a beta of -0.8, indicating that its stock price is 180% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Inhibikase Therapeutics has lower revenue, but higher earnings than Barinthus Biotherapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Barinthus Biotherapeutics beats Inhibikase Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BRNS) was last updated on 7/8/2025 by MarketBeat.com Staff
Free BRNS Stock Alerts